Compare Ganges Securitie with Similar Stocks
Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.01%
- Poor long term growth as Operating profit has grown by an annual rate of -30.66%
Negative results in Sep 25
With ROE of 0.2, it has a Very Expensive valuation with a 0.2 Price to Book Value
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
Ganges Securitie for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Ganges Securities Ltd is Rated Strong Sell
Ganges Securities Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Ganges Securities Ltd Falls to 52-Week Low of Rs.109.6 Amidst Weak Financial Metrics
Ganges Securities Ltd, a player in the FMCG sector, recorded a fresh 52-week low of Rs.109.6 today, marking a significant milestone in its ongoing price decline. The stock’s performance continues to lag behind broader market indices and sector peers, reflecting persistent challenges in its financial metrics and valuation.
Read full news article
Ganges Securities Ltd Falls to 52-Week Low of Rs.117.1 Amidst Continued Downtrend
Ganges Securities Ltd, a player in the FMCG sector, recorded a new 52-week low of Rs.117.1 today, marking a significant decline in its stock price amidst a volatile trading session and ongoing underperformance relative to its sector and broader market indices.
Read full news article Announcements 
Board Meeting Intimation for Notice Of Board Meeting
02-Feb-2026 | Source : BSEGanges Securities Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday February 11 2026 inter-alia to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended on December 31 2025. This is for your information and records.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
06-Jan-2026 | Source : BSECertificate under Regulation 74(5) of SEBI (DP) Regulations 2018
Closure of Trading Window
29-Dec-2025 | Source : BSEClosure of trading window
Corporate Actions 
(11 Feb 2026)
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.01%)
Held by 1 FIIs (0.03%)
Sil Investments Limited (13.38%)
Navjeewan Medical Institute (6.21%)
21.88%
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
YoY Growth in quarter ended Sep 2025 is 2.31% vs 13.73% in Sep 2024
YoY Growth in quarter ended Sep 2025 is -59.70% vs 8.25% in Sep 2024
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -4.41% vs 19.10% in Sep 2024
Growth in half year ended Sep 2025 is -52.87% vs 35.93% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'24
YoY Growth in nine months ended Dec 2024 is 11.81% vs -12.77% in Dec 2023
YoY Growth in nine months ended Dec 2024 is 22.30% vs -39.98% in Dec 2023
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 9.08% vs -15.57% in Mar 2024
YoY Growth in year ended Mar 2025 is 45.40% vs -64.31% in Mar 2024






